Literature DB >> 6849783

Labetalol disposition and concentration-effect relationships during pregnancy.

P C Rubin, L Butters, A W Kelman, C Fitzsimons, J L Reid.   

Abstract

1 Labetalol pharmacokinetics and concentration-effect relationships following intravenous administration have been studied in 10 women during the last trimester of pregnancies complicated by hypertension, in seven of these women postpartum (when normotensive) and in 10 normotensive female volunteers. 2 The clearance and volume of distribution of labetalol were the same in all three groups. Clearance values (1 min-1) were: pregnant, 2.16 (range 1.54-3.14); postpartum 2.35 (1.56-3.85); controls 1.96 (0.98-2.61). Volumes of distribution (1) were: pregnant 274 (250-547); postpartum 407 (248-701); controls 234 (186-415). 3 A linear model relating labetalol concentration to effect successfully described the antihypertensive action of labetalol in the pregnant patients. Supine systolic blood pressure fell by 0.38 (0.14-0.91) mm Hg per ng ml-1 of labetalol and diastolic by 0.36 (0.21-1.14) mm Hg per ng ml-1 of labetalol. In the other two groups labetalol did not lower pressure sufficiently to allow modelling to be performed. 4 We conclude that pregnancy does not alter the clearance or volume of distribution of labetalol. Modelling techniques can be applied successfully to drug induced blood pressure changes during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849783      PMCID: PMC1427790          DOI: 10.1111/j.1365-2125.1983.tb01531.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Investigations into the influence of posture on renal plasma flow and glomerular filtration rate during late pregnancy.

Authors:  W Dunlop
Journal:  Br J Obstet Gynaecol       Date:  1976-01

2.  Induction of hepatic enzymes during normal human pregnancy.

Authors:  M Davis; C J Simmons; B Dordoni; J D Maxwell; R Williams
Journal:  J Obstet Gynaecol Br Commonw       Date:  1973-08

3.  Phenytoin and phenobarbitone plasma clearance during pregnancy.

Authors:  K I Mygind; M Dam; J Christiansen
Journal:  Acta Neurol Scand       Date:  1976-08       Impact factor: 3.209

4.  Antiepileptic drugs: metabolism in pregnancy.

Authors:  M Dam; J Christiansen; O Munck; K I Mygind
Journal:  Clin Pharmacokinet       Date:  1979 Jan-Feb       Impact factor: 6.447

5.  Serum protein changes in the parturient mother, fetus and newborn infant.

Authors:  J W Studd; C M Starkie; J D Blainey
Journal:  J Obstet Gynaecol Br Commonw       Date:  1970-06

6.  Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension.

Authors:  L M Wing; J L Reid; D S Davies; E A Neill; P Tippett; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

7.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

8.  Metabolism of diphenylhydantoin (phenytoin) during pregnancy.

Authors:  M J Landon; M Kirkley
Journal:  Br J Obstet Gynaecol       Date:  1979-02

9.  Effect of pregnancy on the pharmacokinetics of caffeine.

Authors:  R Knutti; H Rothweiler; C Schlatter
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Plasma anticonvulsant concentrations during pregnancy.

Authors:  C M Lander; V E Edwards; M J Eadie; J H Tyrer
Journal:  Neurology       Date:  1977-02       Impact factor: 9.910

View more
  12 in total

Review 1.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

2.  Plasma concentration-effect relationship of metoprolol during and after pregnancy.

Authors:  S Högstedt; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients.

Authors:  Teresa Maria J P Carvalho; Ricardo de Carvalho Cavalli; Sérgio P Cunha; Cláudia O de Baraldi; Maria P Marques; Natalícia J Antunes; Ana Leonor P C Godoy; Vera Lucia Lanchote
Journal:  Eur J Clin Pharmacol       Date:  2010-09-17       Impact factor: 2.953

Review 4.  The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.

Authors:  Ian R Mulrenin; Julian E Garcia; Muluneh M Fashe; Matthew Shane Loop; Melissa A Daubert; Rachel Peragallo Urrutia; Craig R Lee
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-11       Impact factor: 4.481

Review 5.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 6.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

7.  Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.

Authors:  James H Fischer; Gloria E Sarto; Jennifer Hardman; Loraine Endres; Thomas M Jenkins; Sarah J Kilpatrick; Hyunyoung Jeong; Stacie Geller; Kelly Deyo; Patricia A Fischer; Keith A Rodvold
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.

Authors:  R Donnelly; G J Macphee
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 9.  Effect of pregnancy on the pharmacokinetics of antihypertensive drugs.

Authors:  Gail D Anderson; Darcy B Carr
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.